A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
- PMID: 11205899
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
Abstract
The absence or the presence of low levels of the Coxsackievirus and adenovirus receptor (CAR) on several tumor types might limit the efficacy of recently proposed tumor-specific or conditionally replicative adenoviruses (CRAds). To address this issue, we used a genetic modification of the fiber knob in the context of an E1A-defective CRAd to allow CAR-independent target cell infection as a means to enhance oncolytic potency. Such infectivity-enhanced CRAd showed higher replication, more efficient infection, and lysis of tumor cells in vitro. Of note, the improved antitumor effect of the fiber-modified CRAd could be demonstrated in vivo. We conclude that the combination of genomic modification to achieve tumor-selective replication and capsid modification to enhance infectivity yields more potent oncolytic adenoviruses for use in cancer treatment.
Similar articles
-
E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.Clin Cancer Res. 2007 May 15;13(10):3043-50. doi: 10.1158/1078-0432.CCR-06-2103. Clin Cancer Res. 2007. PMID: 17505007
-
Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.Int J Cancer. 2007 Feb 15;120(4):935-41. doi: 10.1002/ijc.22338. Int J Cancer. 2007. PMID: 17131341
-
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.Clin Cancer Res. 2002 Nov;8(11):3348-59. Clin Cancer Res. 2002. PMID: 12429621
-
Engineering regulatory elements for conditionally-replicative adeno-viruses.Curr Gene Ther. 2003 Aug;3(4):357-85. doi: 10.2174/1566523034578311. Curr Gene Ther. 2003. PMID: 12871022 Review.
-
Conditionally replicative adenovirus for gastrointestinal cancers.Expert Opin Biol Ther. 2004 Aug;4(8):1241-50. doi: 10.1517/14712598.4.8.1241. Expert Opin Biol Ther. 2004. PMID: 15268659 Review.
Cited by
-
Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.J Virol. 2020 Nov 9;94(23):e01703-20. doi: 10.1128/JVI.01703-20. Print 2020 Nov 9. J Virol. 2020. PMID: 32907973 Free PMC article.
-
Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Front Oncol. 2013 Feb 25;3:32. doi: 10.3389/fonc.2013.00032. eCollection 2013. Front Oncol. 2013. PMID: 23443138 Free PMC article.
-
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.Br J Cancer. 2006 Jun 19;94(12):1837-44. doi: 10.1038/sj.bjc.6603189. Epub 2006 May 30. Br J Cancer. 2006. PMID: 16736005 Free PMC article.
-
Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.Lung Cancer. 2007 Feb;55(2):145-56. doi: 10.1016/j.lungcan.2006.10.012. Epub 2006 Nov 17. Lung Cancer. 2007. PMID: 17113184 Free PMC article.
-
A three-dimensional assay for measurement of viral-induced oncolysis.Cancer Gene Ther. 2007 Apr;14(4):421-30. doi: 10.1038/sj.cgt.7701028. Epub 2007 Jan 19. Cancer Gene Ther. 2007. PMID: 17235353 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical